INBX - Inhibrx, Inc. Stock Price, Fair Value and News

13.72USD+0.29 (+2.16%)Market Closed

Market Summary

USD13.72+0.29

Market Closed

2.16%

INBX Stock Price

View Fullscreen

INBX RSI Chart

INBX Valuation

Market Cap

719.0M

Price/Earnings (Trailing)

-2.65

Price/Sales (Trailing)

61.17

EV/EBITDA

-2.5

Price/Free Cashflow

-3.24

INBX Price/Sales (Trailing)

INBX Profitability

EBT Margin

-2261.63%

Return on Equity

-2.3K%

Return on Assets

-93.96%

Free Cashflow Yield

-30.89%

INBX Fundamentals

INBX Revenue

Revenue (TTM)

11.9M

Rev. Growth (Yr)

33.06%

Rev. Growth (Qtr)

9.86%

INBX Earnings

Earnings (TTM)

-271.2M

Earnings Growth (Yr)

-60.91%

Earnings Growth (Qtr)

15.91%

Breaking Down INBX Revenue

Last 7 days

3.8%

Last 30 days

-10.7%

Last 90 days

-60.4%

Trailing 12 Months

-40.6%

How does INBX drawdown profile look like?

INBX Financial Health

Current Ratio

3.82

Debt/Equity

17.68

Debt/Cashflow

-1.06

INBX Investor Care

Shares Dilution (1Y)

20.14%

Diluted EPS (TTM)

-5.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	3.7M	5.3M	8.6M	11.9M
2022	7.3M	5.5M	3.8M	2.1M
2021	12.9M	10.5M	7.2M	7.2M
2020	13.1M	13.0M	13.0M	12.9M
2019	0	0	0	13.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

CEO	Mr. Mark Paul Lappe
WEBSITE	https://inhibrx.com
INDUSTRY	Biotechnology
EMPLOYEES	132

Inhibrx, Inc. Frequently Asked Questions

What is the ticker symbol for Inhibrx, Inc.? What does INBX stand for in stocks?

INBX is the stock ticker symbol of Inhibrx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inhibrx, Inc. (INBX)?

As of Thu Jul 25 2024, market cap of Inhibrx, Inc. is 703.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INBX stock?

You can check INBX's fair value in chart for subscribers.

Is Inhibrx, Inc. a good stock to buy?

The fair value guage provides a quick view whether INBX is over valued or under valued. Whether Inhibrx, Inc. is cheap or expensive depends on the assumptions which impact Inhibrx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INBX.

What is Inhibrx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, INBX's PE ratio (Price to Earnings) is -2.6 and Price to Sales (PS) ratio is 61.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INBX PE ratio will change depending on the future growth rate expectations of investors.